MA51221A - Composés de pyrazolopyridinone - Google Patents

Composés de pyrazolopyridinone

Info

Publication number
MA51221A
MA51221A MA051221A MA51221A MA51221A MA 51221 A MA51221 A MA 51221A MA 051221 A MA051221 A MA 051221A MA 51221 A MA51221 A MA 51221A MA 51221 A MA51221 A MA 51221A
Authority
MA
Morocco
Prior art keywords
pyrazolopyridinone
compounds
pyrazolopyridinone compounds
Prior art date
Application number
MA051221A
Other languages
English (en)
Inventor
Wing Shun Cheung
Haibing Guo
Qian Liu
Luoheng Qin
Zhao-Kui Wan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA51221A publication Critical patent/MA51221A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
MA051221A 2017-11-24 2018-11-23 Composés de pyrazolopyridinone MA51221A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2017112836 2017-11-24

Publications (1)

Publication Number Publication Date
MA51221A true MA51221A (fr) 2020-10-07

Family

ID=66630494

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051221A MA51221A (fr) 2017-11-24 2018-11-23 Composés de pyrazolopyridinone

Country Status (12)

Country Link
US (2) US11384099B2 (fr)
EP (1) EP3717483B1 (fr)
JP (1) JP7329510B2 (fr)
KR (1) KR102723359B1 (fr)
CN (1) CN111655689B (fr)
AU (1) AU2018370904B2 (fr)
BR (1) BR112020010004A2 (fr)
CA (1) CA3084528A1 (fr)
ES (1) ES2963339T3 (fr)
MA (1) MA51221A (fr)
MX (1) MX2020005342A (fr)
WO (1) WO2019101183A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102763767B1 (ko) * 2017-11-24 2025-02-05 얀센 파마슈티카 엔브이 피라졸로피리디논 화합물
WO2020135483A1 (fr) * 2018-12-26 2020-07-02 Janssen Pharmaceutica Nv Composés de thiénopyridinone
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法
TW202246284A (zh) * 2021-03-10 2022-12-01 大陸商山東軒竹醫藥科技有限公司 三并環類hpk1抑制劑及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221683A (en) 1984-03-19 1993-06-22 The Rockefeller University Diaminopyridine compounds and methods of use
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP0951541B1 (fr) 1995-07-31 2005-11-30 Urocor, Inc. Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
JP3539424B2 (ja) * 2002-07-24 2004-07-07 日産自動車株式会社 電気自動車の制御装置
EP1539754A4 (fr) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic Quinolinones de benzimidazole et leurs utilisations
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
US20050209247A1 (en) 2003-11-07 2005-09-22 Chiron Corporation Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds

Also Published As

Publication number Publication date
ES2963339T3 (es) 2024-03-26
JP7329510B2 (ja) 2023-08-18
JP2021504332A (ja) 2021-02-15
AU2018370904A1 (en) 2020-05-14
RU2020120796A (ru) 2021-12-24
KR20200090828A (ko) 2020-07-29
EP3717483A1 (fr) 2020-10-07
CA3084528A1 (fr) 2019-05-31
EP3717483B1 (fr) 2023-09-06
US20220340598A1 (en) 2022-10-27
WO2019101183A1 (fr) 2019-05-31
CN111655689B (zh) 2023-01-06
EP3717483A4 (fr) 2021-07-14
CN111655689A (zh) 2020-09-11
MX2020005342A (es) 2020-10-14
US20210147446A1 (en) 2021-05-20
BR112020010004A2 (pt) 2020-10-13
KR102723359B1 (ko) 2024-10-28
US11384099B2 (en) 2022-07-12
AU2018370904B2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
EP3691623A4 (fr) Composés de benzosulfonyle
EP3720430A4 (fr) Composés benzocarbonyle
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52948A (fr) Composés
MA49701A (fr) Composés immunomodulateurs
MA51669A (fr) Composés
MA42293A (fr) Composés antibactériens
EP3532069A4 (fr) Composés aryl-amide phosphodiamide antiviraux
EP3474845A4 (fr) Composés immunomodulateurs
MA53003A (fr) Composés
MA44020A (fr) Composés antitumoraux
ME03419B (fr) Composés dihydroisoquinolinone substitués
EP3609871A4 (fr) Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
MA50504A (fr) Composés antibactériens
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3728289A4 (fr) Composés optimisés
EP3464336A4 (fr) Composés
MA49621A (fr) Composés bifonctionnels
MA52946A (fr) Composés
EP3405455A4 (fr) Composés de 2-oxindole
EP3713941A4 (fr) Composés de pyrazolopyridinone
EP3717483A4 (fr) Composés de pyrazolopyridinone
MA49522A (fr) Nouveaux composés de quinoléinone
MA49885A (fr) Composés macrocycliques
EP3504269A4 (fr) Composés de fluoroélastomère